NetScientific PLC ProAxsis awarded Innovate UK grant (1279I)

TIDMNSCI

RNS Number : 1279I

NetScientific PLC

10 December 2020

NetScientific plc

("NetScientific" or the "Company")

ProAxsis Limited awarded Innovate UK grant to utilise company technology to identify high risk COVID-19 patients

London, UK - 10 December 2020 - NetScientific plc (AIM: NSCI), the life sciences, technology, investment and commercialisation company, announces that its portfolio company ProAxsis Limited ("ProAxsis"), announced that it has been awarded a high impact Innovate UK grant as part of the recent "UKRI Ideas to Address COVID-19" competition. The company will immediately initiate the GBP390,000 project, which will be co-funded by Innovate UK, to develop novel protease biomarkers to identify high-risk patients.

ProAxsis is established at the forefront of respiratory diagnostics, with clients in the Pharma and clinical trials markets. Its R&D pipeline is reinforcing this position by expanding the applicability of its technology - including around the use of its biomarkers platform to help in the fight against COVID-19.

This further development activity supports the goal for ProAxsis to fully establish itself as the leading commercial protease diagnostic provider of choice globally. The grant support enables ProAxsis to expand its services available to the growing global client list of pharmaceutical companies and academic laboratories, enhance the NEATstik(R) point of care test, and realise the opportunities in the COVID-19 response.

Gavin Robinson, MP for Belfast East, said: " Last week we received positive news that the UK would be rolling out a vaccine this side of Christmas. I am delighted that this week, ProAxsis based in East Belfast have been successful in their application for an Innovate UK grant. A huge congratulations to the dedicated team for this notable achievement."

John Clarkson, Chairman of NetScientific and ProAxsis, commented: "This is the 5(th) independently assessed grant awarded to the company in 2020, enabling partial funding support of projects with a total overall value of over GBP1 million. Despite the challenging environment and lockdown interruption, ProAxsis has made strong progress this year and this latest announcement illustrates the increased commercial potential for its respiratory diagnostics offering in a post-COVID-19 world. The other awards include:

1. An Innovate UK rapid GBP50,000 grant for Cytokine multiplexing in sputum to help identify critical signs of clinical deterioration for patients infected with COVID-19.

2. A GBP200k+ R&D project with Invest Northern Ireland, seeking to create new diagnostic tests for chronic human respiratory diseases.

3. 12-month collaboration with the Northern Ireland Connected Health Innovation Centre (CHIC), on a R&D project designed to enhance NEATstik(R), our point-of-care diagnostic test.

4. 12-week project with the Eastern Corridor Medical Engineering (ECME) Centre at Ulster University, targeted at completing the final validation of the Cathepsin G immunoassay."

NetScientific holds 95% of ProAxsis on a fully diluted basis.

The full text of the announcement from ProAxsis can be found below.

# # #

ProAxsis ( www.proaxsis.com ) , the Belfast-based respiratory diagnostics company, today announces that it has been awarded a high impact Innovate UK grant as part of the recent " UKRI Ideas to Address COVID-19 " competition. The company will immediately initiate the GBP390,000 project, which will be co-funded by Innovate UK, to develop novel protease biomarkers to identify high-risk patients.

Speaking about the plans, Dr David Ribeiro, CEO of ProAxsis, said:

"Recognition of this kind from Innovate UK, the UK's innovation agency, is an enormous testament to the cutting-edge research being conducted by the ProAxsis team of scientists at its purpose-built laboratory in Belfast. This project is targeted at utilising the company's unprecedented expertise in active protease biomarkers to enable clinicians to identify which patients are at highest risk of experiencing significant symptoms when they become infected with COVID-19, as well as creating novel diagnostic tools for measuring the effectiveness of potential therapies. This award will drive significant expansion of the company's R&D activities and builds on our existing work on inflammatory biomarkers associated with COVID-19."

Dr Ribeiro added:

"The awarding of this grant, alongside the strong support of our parent company, Netscientific plc, has enabled the company to immediately expand its team in Belfast with the recruitment of additional R&D scientists. As a first step, we welcome Ciaran McGranaghan, who recently graduated with a First Class Honours degree in Biological Sciences from Queen's University Belfast."

Gavin Robinson, MP for Belfast East, said: " Last week we received positive news that the UK would be rolling out a vaccine this side of Christmas. I am delighted that this week, ProAxsis based in East Belfast have been successful in their application for an Innovate UK grant. A huge congratulations to the dedicated team for this notable achievement."

Any enquiries concerning ProAxsis' work on COVID-19 can be directed to [e-mail].

About ProAxsis

ProAxsis Limited is a commercial-stage diagnostics company, based in Northern Ireland, and with a rapidly growing global client list of pharmaceutical companies and academic laboratories. The company has registered a CE Mark for activity-based immunoassays targeting Neutrophil Elastase (NE) and Proteinase 3, as biomarkers of lung infection and inflammation in chronic respiratory diseases such as COPD, cystic fibrosis and bronchiectasis.

This technology has been translated into a point-of-care test (NEATstik(R)), to enable ongoing monitoring of active NE levels. Recently published data has shown that measuring active NE levels using NEATstik(R) enables identification of patients with airway bacterial infection and those patients at highest risk of suffering pulmonary exacerbations over the subsequent 12 months.

In addition to proteases, the company also has significant expertise in the measurement of other inflammatory biomarkers, including IL-6, IL-8 and TNF-alpha. Grant-funded R&D funded projects for a variety of targets remain a key area of focus.

Aside from the provision of assays, ProAxsis can offer sample analysis at its purpose-built laboratory facility in Belfast and is currently supporting a number of pharmaceutical company-sponsored Phase I, II and III clinical trials.

ProAxsis became a fully owned subsidiary of Netscientific plc in October 2020.

About Innovate UK

Innovate UK drives productivity and economic growth by supporting businesses to develop and realise the potential of new areas. We connect businesses to the partners, customers and investors that can help them turn ideas into commercially successful products and services and business growth.

We fund business and research collaborations to accelerate innovation and drive business investment into R&D. Our support is available to businesses across all economic sectors, value chains and UK regions.

Innovate UK is part of UK Research and Innovation. For more information, please visit www.innovateuk.ukri.org

# # #

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Following the publication of this announcement, this inside information is now considered to be in the public domain.

For more information, please contact:

NetScientific

Ilian Iliev, CEO Tel: [phone]

WH Ireland (NOMAD, Financial Adviser and Broker)

Chris Fielding / Darshan Patel Tel: [phone]

About NetScientific

NetScientific is a life sciences, technology, investment and commercialisation Group, leveraging trans-Atlantic relationships and global opportunities to deliver shareholder value.

For more information, please visit the website at www.NetScientific.net

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCUKANRRWUURAA

(END) Dow Jones Newswires

December 10, 2020 02:00 ET (07:00 GMT)